risdiplam Archives - Knowledge Ecology International

Proposal for Addition Of Risdiplam to WHO Model List Of Essential Medicines, for the treatment of Spinal Muscular Atrophy (SMA).

Posted on November 1, 2024 by Arianna Schouten

On November 1, 2024, Knowledge Ecology International (KEI) submitted a proposal for the addition of risdiplam to the World Health Organization’s (WHO) Model List of Essential Medicine (EML). You can access the full proposal here: risdiplam2WHOEML1Nov2024 The EML, updated every… Continue Reading →

KEI asks WHO to include risdiplam, treatment for Spinal Muscular Atrophy, on the Essential Medicines List (EML)

Posted on November 15, 2022 by KEI Staff

KEI has petitioned the World Health Organization (WHO) to include risdiplam, a drug to treat Spinal Muscular Atrophy (SMA), on its Essential Medicines List (EML), in a category for products that should be accessible if available at affordable prices. Risdiplam-EML-2022-KEI

KEI letter to Roche requesting voluntary license to patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA)

Posted on July 8, 2022 by James Love

This is a letter to Roche requesting a voluntary license to the patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA). KEI-Risdiplan-patent-license-request-8july2022 This was the August 5, 2022 response from Roche. Roche-Response-to-Risdiplam-license-request–5Aug2022 KEI wrote to Roche again on February… Continue Reading →

risdiplam

Risdiplam, originally developed under contract with the SMA Foundation by PTC Therapeutics and licensed to Roche for sale under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy and the first oral medication approved to treat… Continue Reading →

Categories